JPWO2019002421A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019002421A5
JPWO2019002421A5 JP2019571649A JP2019571649A JPWO2019002421A5 JP WO2019002421 A5 JPWO2019002421 A5 JP WO2019002421A5 JP 2019571649 A JP2019571649 A JP 2019571649A JP 2019571649 A JP2019571649 A JP 2019571649A JP WO2019002421 A5 JPWO2019002421 A5 JP WO2019002421A5
Authority
JP
Japan
Prior art keywords
topical
preparation
use according
formulation
galactooligosaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019571649A
Other languages
Japanese (ja)
Other versions
JP7170002B2 (en
JP2020525460A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/067337 external-priority patent/WO2019002421A1/en
Publication of JP2020525460A publication Critical patent/JP2020525460A/en
Publication of JPWO2019002421A5 publication Critical patent/JPWO2019002421A5/ja
Application granted granted Critical
Publication of JP7170002B2 publication Critical patent/JP7170002B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

治療に使用するための局所製剤であって、
・ガラクトオリゴ糖と、
・０．０１％～１０％ｗ／ｗのキシリトールと、
・製薬上または化粧品として許容される担体と、を含む、局所製剤。 A topical preparation for use in treatment
・ Galactooligosaccharide and
-With 0.01% to 10% w / w xylitol,
-Topical formulations containing, pharmaceutically or cosmetically acceptable carriers. 前記製剤が０．０１％～５％ｗ／ｗのキシリトールを含む、請求項１に記載の使用のための局所製剤。 The topical formulation for use according to claim 1, wherein the formulation comprises 0.01% to 5% w / w xylitol. 前記製剤が０．０１％～１０％ｗ／ｗのガラクトオリゴ糖を含む、請求項１または２に記載の使用のための局所製剤。 The topical preparation for use according to claim 1 or 2, wherein the preparation comprises 0.01% to 10% w / w of galactooligosaccharides. 前記製剤が０．０１％～５％ｗ／ｗのガラクトオリゴ糖を含む、請求項１～３のいずれか一項に記載の使用のための局所製剤。 The topical preparation for use according to any one of claims 1 to 3, wherein the preparation contains 0.01% to 5% w / w of galactooligosaccharide. 前記製剤は、ガラクトオリゴ糖：キシリトールの重量比が１０：１～１：１０である、請求項１～４のいずれか一項に記載の使用のための局所製剤。 The local preparation for use according to any one of claims 1 to 4, wherein the preparation has a weight ratio of galactooligosaccharide: xylitol of 10: 1 to 1:10. 前記製剤は、ガラクトオリゴ糖：キシリトールの重量比が２：１～１：２である、請求項１～５のいずれか一項に記載の使用のための局所製剤。 The formulation is a topical formulation for use according to any one of claims 1 to 5, wherein the galactooligosaccharide: xylitol weight ratio is 2: 1 to 1: 2. 前記複合物がエマルション、皮膚軟化剤、ペースト剤、クリーム剤、軟膏、またはゲル剤である、請求項１～６のいずれか一項に記載の使用のための局所製剤。 The topical preparation for use according to any one of claims 1 to 6, wherein the complex is an emulsion, a emollient, a paste, a cream, an ointment, or a gel. 前記製剤が水中油型エマルジョンまたは油中水型エマルジョンである、請求項１～７のいずれか一項に記載の使用のための局所製剤。 The topical preparation for use according to any one of claims 1 to 7, wherein the preparation is an oil-in- water emulsion or a water-in-oil emulsion. 前記製剤が水中油型エマルションである、請求項１～８のいずれか一項に記載の使用のための局所製剤。The topical preparation for use according to any one of claims 1 to 8, wherein the preparation is an oil-in-water emulsion. 局所塗布による治療に使用するための、請求項１～９のいずれか一項に記載の使用のための局所製剤。 The topical preparation for use according to any one of claims 1 to 9 , for use in the treatment by topical application. 局所製剤であって、
・ガラクトオリゴ糖と、
・キシリトールと、
・製薬上または化粧品として許容される担体と、を含む、
局所塗布による治療に使用するための、局所製剤。 It is a topical preparation
・ Galactooligosaccharide and
・ With xylitol
· Includes pharmaceutical or cosmetically acceptable carriers,
A topical preparation for use in treatment by topical application. 前記製剤が皮膚疾患または障害の治療用である、請求項１１に記載の使用のための局所製剤。 The topical formulation for use according to claim 11 , wherein the formulation is for the treatment of a skin disorder or disorder. 前記皮膚疾患または障害が、黄色ブドウ球菌に関連付けられる疾患または障害である、請求項１２に記載の使用のための局所製剤。 The topical formulation for use according to claim 12 , wherein the skin disease or disorder is a disease or disorder associated with Staphylococcus aureus. 前記皮膚疾患または障害がアトピー性皮膚炎である、請求項１２または１３に記載の使用のための局所製剤。 The topical formulation for use according to claim 12 or 13, wherein the skin disease or disorder is atopic dermatitis. ・ガラクトオリゴ糖と、
・０．０１％～１０％ｗ／ｗのキシリトールと、
・製薬上または化粧品として許容される担体と、を含む、局所製剤の、局所塗布による化粧品としての使用。 ・ Galactooligosaccharide and
-With 0.01% to 10% w / w xylitol,
-Use of topical formulations as cosmetics by topical application, including pharmaceutically or cosmetically acceptable carriers .
JP2019571649A 2017-06-27 2018-06-27 Antibacterial activity of galacto-oligosaccharides and xylitol in dermatological treatment Active JP7170002B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762525489P 2017-06-27 2017-06-27
US62/525,489 2017-06-27
PCT/EP2018/067337 WO2019002421A1 (en) 2017-06-27 2018-06-27 Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments

Publications (3)

Publication Number Publication Date
JP2020525460A JP2020525460A (en) 2020-08-27
JPWO2019002421A5 true JPWO2019002421A5 (en) 2022-02-15
JP7170002B2 JP7170002B2 (en) 2022-11-11

Family

ID=62816525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571649A Active JP7170002B2 (en) 2017-06-27 2018-06-27 Antibacterial activity of galacto-oligosaccharides and xylitol in dermatological treatment

Country Status (10)

Country Link
US (1) US11234997B2 (en)
EP (2) EP3644945B1 (en)
JP (1) JP7170002B2 (en)
KR (1) KR20200024786A (en)
AU (1) AU2018293307B2 (en)
BR (1) BR112019027089B1 (en)
ES (1) ES2948510T3 (en)
NZ (1) NZ759173A (en)
PH (1) PH12019502874A1 (en)
WO (1) WO2019002421A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201900031D0 (en) * 2019-01-02 2019-02-13 Rottapharm Spa Antibacterial oral compositions
GB201911071D0 (en) * 2019-08-02 2019-09-18 Meda Pharma S P A Antibacterial activity of selected prebiotic oligosaccharides and xylitol in dermatological treatment
BR112022014624A2 (en) * 2020-02-25 2022-09-13 Unilever Ip Holdings B V USES OF A COMBINATION OF A SACCHARIDE AND GLYCEROL AND METHOD OF PROTECTION OF THE SKIN AGAINST NON-COMMENSAL BACTERIA
DE102020133860A1 (en) 2020-12-16 2022-06-23 MNT Systeme GmbH USE OF β-GALACTOOLIGOSACCHRIDS FOR THE PREPARATION OF A COSMETIC AND/OR PHARMACOLOGICALLY ACTIVE COMPOSITION
JPWO2022230925A1 (en) * 2021-04-28 2022-11-03

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678166B1 (en) * 1991-06-27 1993-10-22 Bioeurope COSMETIC COMPOSITIONS CONTAINING GLUCOOLIGOSACCHARIDES.
JP4011787B2 (en) * 1999-04-22 2007-11-21 株式会社資生堂 Selective antimicrobial composition
JP2000302673A (en) * 1999-04-22 2000-10-31 Shiseido Co Ltd Preparation for external use for skin for atopic dermatitis
JP2002302404A (en) * 2001-04-02 2002-10-18 Shiseido Co Ltd Antibacterial and antifungal assistant
JP2008156308A (en) * 2006-12-26 2008-07-10 Lion Corp Composition for oral cavity
JP5207664B2 (en) * 2007-06-04 2013-06-12 株式会社シャネル化粧品技術開発研究所 Cosmetics
EP2814457A2 (en) 2012-02-14 2014-12-24 The Procter and Gamble Company Topical use of a skin-commensal prebiotic agent and compositions containing the same
CN103462881B (en) * 2013-10-10 2016-06-22 深圳市容大生物技术有限公司 A kind of composition and method of making the same promoting skin microecological balance
JP2016196435A (en) * 2015-04-06 2016-11-24 コーベビオケミア株式会社 Skin care composition
CN104970176A (en) 2015-07-02 2015-10-14 广州普正生物科技有限公司 A compound fungus polysaccharide gel candy
CN105796377A (en) * 2016-03-18 2016-07-27 西安膳方医药科技有限公司 Method for improving biological body surface health through micro-ecology adjustment
JP2019515886A (en) * 2016-03-31 2019-06-13 ゴジョ・インダストリーズ・インコーポレイテッド Topical composition for reducing pathogen binding
CN106071033A (en) * 2016-05-12 2016-11-09 南京泽朗生物科技有限公司 A kind of ice cream containing prebiotics and preparation method thereof
CN106616602A (en) * 2016-12-09 2017-05-10 宁夏沃福百瑞枸杞产业股份有限公司 Preparation method of black Chinese wolfberry fruit probiotic tablets

Similar Documents

Publication Publication Date Title
JP2668800B2 (en) Topical treatment for skin diseases
US20170087073A1 (en) Mild leave-on skin care compositions
JP2013511534A5 (en)
BRPI0611713A2 (en) topical skin care compositions
US20200093785A1 (en) Skin care compositions and methods
US8846646B2 (en) Topical treatment of skin infection
JP2022546928A (en) TOPICAL FORMULATIONS CONTAINING CANNABIDIOL, METHODS FOR PREPARATION OF COMPOSITIONS AND USES THEREOF
EA017856B1 (en) Compositions for the treatment of hair loss
JPWO2019002421A5 (en)
US20200030398A1 (en) Skin care composition
ES2379474T3 (en) Dermatological product for the treatment and / or skin care with neurodermitis
BR112020020541A2 (en) TOPICAL FORMULATIONS THAT UNDERSTAND STRENGTH AND METHYLPHONYL METHANE (MSM) AND TREATMENT METHODS
US20090312429A1 (en) Administration of nepafenac or derivatives thereof for treating dermatological/keratinization disorders
WO2005007071A2 (en) Skin formulation
ITUB20159582A1 (en) Composition, for topical use, useful for the prevention of inflammatory and / or infectious mucosal disorders.
JPH0429934A (en) Externally applicable composition containing extracted essence of ginkgo leaf
JP2021502420A5 (en)
WO2015040637A1 (en) Improved coal tar formulation for treatment of dandruff and other scalp diseases and its method of preparation thereof
JP6175067B2 (en) New use of neohesperidin
RU2020102673A (en) ANTIBACTERIAL ACTIVITY OF GALACTOOLIGOSACCHARIDE AND XYLITOL IN DERMATOLOGICAL TREATMENTS
RU2611346C1 (en) Method of treating demodectosis
WO2019242705A1 (en) Skin hydration composition
KR20230088727A (en) Permethrin for use in the treatment of Demodex species infection
BR102020021151A2 (en) formulation for antiseptic cream with moisturizing properties
JP2006522057A5 (en)